A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects

NCT03156101 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed B-cell Acute Lymphoblastic Leukemia
Refractory B-cell Acute Lymphoblastic Leukemia
Relapsed／Refractory B-cell Lymphoma

Interventions

BIOLOGICAL: BinD19

Sponsor

Shenzhen BinDeBio Ltd.

Collaborators

[object Object]